Pharmacotherapy Follow up in Mental Health: Which Outcomes Change in a Short Period?

    Published on:December 2020
    Journal of Young Pharmacists, 2020; 12(4):373-378
    Original Article | doi:10.5530/jyp.2020.12.95
    Authors:

    Sheilla Alessandra Ferreira Fernandes1,*, Giselle de Carvalho Brito2, Chiara Erminia da Rocha2, Renato Melo Torres3, Aurigena Antunes de Araújo4, Marta Maria de França Fonteles1,5

    1Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacia, Federal University of Ceará, Ceará, BRAZIL.

    2Department of Pharmacy, Federal University of Sergipe, Lagarto, BRAZIL.

    3Materials Division / Dean of Administration, Federal University of Semi-arid, UFERSA, Rio Grande do Norte, BRAZIL.

    4Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Rio Grande do Norte, BRAZIL.

    5Department of Pharmacy, Federal University of Ceará, Ceará, BRAZIL.

    Abstract:

    Objectives: Investigate the outcome changes in patients with depression and anxiety during a pharmacotherapy follow up service, in a short period. Materials and Methods: A randomized and controlled trial of 70 adults was developed in Psychosocial Care Centers in Brazil. Patients in the intervention group received pharmacotherapy follow up service according over a 4-month period. The control group received traditional service. After the 4-month period, patients of the control group were invited to participate for another four months receiving pharmacotherapy follow up service (control group post-intervention). The primary outcomes (medication adherence, anxiety and depression rates, quality of life) and the variations between groups were compared. Results: The evaluation of the control group data showed no statistically significant difference for parameters. However, in relation to adherence to pharmacotherapy, there was a statistically significant difference in the intervention group, between consultations 1 and 3 and consultations 1 and 4. For the clinical parameters (depression and anxiety) and humanistic (quality of life), there was no difference between the intervention group consultations. For the patients in the control group post-intervention (consultations 1 to 4), when compared to moment 4 of the control group, the levels of depression decreased between the moment 4 control group and the moments of the pharmaceutical appointment 2, 3 and 4. Conclusion: This study points out that these patients should take much more time being followed up, in order to improve the clinical and humanistic outcomes. Also, standardized documentation and records have to be provided in this pharmaceutical service.

    Article Download

     

    Navigation